bioAffinity Technologies, Inc. 8-K

What Happened bioAffinity Technologies, Inc. (BIAF) filed an 8-K (Item 8.01) on March 25, 2026 reporting that it issued a press release announcing a live virtual physician roundtable. The event will feature pulmonologists who will discuss how they use the company’s CyPath® Lung test in clinical practice for lung cancer risk assessment, pulmonary nodule management, and surveillance of lung cancer survivors after treatment. The press release is attached as Exhibit 99.1 to the filing.

Key Details

• Filing date: March 25, 2026 (Form 8-K, Item 8.01).
• Event type: live virtual physician roundtable featuring pulmonologists.
• Topics: clinical use of CyPath® Lung for lung cancer risk assessment, pulmonary nodule management, and post-treatment surveillance.
• Exhibit: Press release dated March 25, 2026 filed as Exhibit 99.1.

Why It Matters The 8-K documents that bioAffinity is actively engaging physician audiences about CyPath® Lung, its clinical application and role in lung cancer management. For investors, this confirms the company is pursuing clinician outreach and public communications around its diagnostic product—an operational activity relevant to product awareness and clinical adoption efforts. The filing does not include financial results or other material changes.